Acetylated HOXB13 Regulated Super Enhancer Genes Define Therapeutic Vulnerabilities of Castration-Resistant Prostate Cancer
Abstract
Androgen receptor (AR) antagonism is exacerbated by HOXB13 in castration-resistant prostate cancers (CRPC). However, it is unclear when and how HOXB13 primes CRPCs for AR antagonism. By mass-spectrometry analysis of CRPC extract, we uncovered a novel lysine 13 (K13) acetylation in HOXB13 mediated by CBP/p300. To determine whether acetylated K13-HOXB13 is a clinical biomarker of CRPC development, we characterized its role in prostate cancer biology.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 18, 2022
- Source ID
- 10.1158/1078-0432.ccr-21-3603
Entities
People
- Cody Weimholt
- Duminduni H. Angappulige
- Duy T. Nguyen
- Eric H. Kim
- Gerald L. Andriole
- Kiran Mahajan
- Nupam P. Mahajan
- Renganathan Arun
- Robert Sprung
- Thanh Nguyen
- Wei Yang
Organizations
- Baylor College of Medicine
- Johns Hopkins School of Medicine
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Institute of General Medical Sciences
- National Institutes of Health
- United States Department of Defense
- Washington University School of Medicine
- Washington University in St. Louis